Sign inJoin waitlistJoin the waitlist

Sarbjit S. Saini

Program Director · Johns Hopkins University School of Medicine

Credentials: · · ·

History

Program Director · Johns Hopkins University School of Medicine
2008–Present
Johns Hopkins University School of Medicine
Present

Johns Hopkins University School of Medicine
Until 1997
University of Michigan Medicine
Until 1994
The OSU Wexner Medical Center
1991

Research

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Allergy · 2022 · 933 citations
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Allergy · 2018 · 918 citations
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
New England Journal of Medicine · 2013 · 812 citations

Jonathan Bernstein
22 papers
Eric Oliver
17 papers
Allen Kaplan
15 papers
Lisa Beck
11 papers
Bruce Bochner
8 papers
DL
David Lang
8 papers
DB
Diane Baker
8 papers
Javed Sheikh
8 papers
Giselle Mosnaim
7 papers
Laura Gober
7 papers
JE
John Eckman
6 papers
Sameer Mathur
6 papers · 6 as a resident

Grants

Role of IgE Bearing Cells in Chronic Idiopathic Urticaria
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $1.4M · Johns Hopkins University
2016–2020
Biomarkers of Severe Peanut Allergy
National Institute of Allergy and Infectious Diseases · R21
Contact PI · $408K · Johns Hopkins University
2010–2013
Mechanisms of Ige Regulation of Human Leukocytes
National Institute of Allergy and Infectious Diseases · K08
Contact PI · $572.5K · Johns Hopkins University
1999–2004

Clinical trials

Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
Principal investigator · Completed · Phase 4
Johns Hopkins University
2017–2020
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
Principal investigator · Completed · Phase 2
Johns Hopkins University
2014–2016
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
Principal investigator · Completed · Phase 4
Johns Hopkins University
2013–2016
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
Principal investigator · Completed · Phase 2
Johns Hopkins University
2009–2013